Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense

August 27, 2014

While many scientists are trying to prevent the onset of a cancer defense mechanism known as autophagy, researchers at Virginia Commonwealth University Massey Cancer Center are leveraging it in a new therapy that causes the process to culminate in cell death rather than survival. The novel treatment strategy targets the p62 protein, which is often referred to as the "Trash Man" due to its role in disposing unwanted cellular proteins during autophagy. Results from preclinical experiments suggest this experimental treatment approach could be particularly effective against multiple myeloma and potentially other forms of blood cancers.

Cancer therapies cause unwanted proteins to accumulate in cancer cells, which can trigger a form of cell suicide known as apoptosis. To survive, the cells break down the excess proteins through , from a Greek term meaning "self eating." In a study recently published in the journal Molecular and Cellular Biology, scientists induced autophagy using the anti-tumor drug obatoclax while simultaneously blocking the production of p62 using a drug known as a cyclin-dependant kinase (CDK) inhibitor. Several experiments involving animal models and cultured cells demonstrated that blocking p62 disrupted autophagy and killed far more cancer cells than administering the anti-cancer agents alone.

"Therapies that are designed to block the early stages of autophagy do not offer the possibility of exploiting its potentially lethal effects," says Steven Grant, M.D., Shirley Carter Olsson and Sture Gordon Olsson Chair in Cancer Research, associate director for translational research and program co-leader of Developmental Therapeutics at VCU Massey Cancer Center. "Our strategy turns autophagy from a protective process into a toxic one, and these results suggest it could increase the effectiveness of a variety of cancer therapies that induce autophagy."

Critical to the success of this therapy is Bik, a protein that plays a significant role in governing and survival. During cancer treatments, Bik accumulates in cancer cells until it triggers apoptosis. Normally, the cancer cells would induce autophagy and p62 would rid the cells of Bik by loading the proteins into degradation chambers known as auotophagosomes for disposal. However, blocking p62 production results in an inefficient form of autophagy and the accumulation of Bik eventually causes the cancer cells to undergo apoptosis.

This research builds upon more than a decade of work by members of Grant's laboratory investigating novel treatment strategies and combination therapies that selectively kill multiple myeloma and other blood . The technology in his study has been made available for licensing through the VCU Office of Research.

"We are now working to identify additional CDK inhibitors that can be used to disrupt autophagy," says Grant. "The ultimate goal will be to translate these findings into a clinical trial to test the therapy in patients with various ."

Explore further: Scientists devise new strategy to destroy multiple myeloma

More information: mcb.asm.org/content/early/2014 … 383-13.full.pdf+html

Related Stories

Scientists devise new strategy to destroy multiple myeloma

August 14, 2012
Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common ...

Cellular 'groundskeeper' considered in cancer fight

July 30, 2014
A greater focus on autophagic activity and metabolism in cancerous cells could make a significant difference in the development of more effective cancer treatments, researchers contend.

Experimental drug could enhance multiple myeloma and myeloid leukemia therapies

February 18, 2014
A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain ...

Malaria medicine chloroquine inhibits tumor growth and metastases

August 11, 2014
A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the ...

Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs

January 10, 2014
(Medical Xpress)—When a tumor is treated with an anti-cancer drug, some cells die and, unfortunately, some cells tend to live. A University of Colorado Cancer Center study published in the journal Nature Cell Biology details ...

Zombie cancer cells eat themselves to live

April 5, 2014
A University of Colorado Cancer Center study recently published in the journal Cell Reports and presented today at the American Association for Cancer Research (AACR) Annual Conference 2014 shows that the cellular process ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.